Literature DB >> 30255720

The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans.

Douglas L Boggs1,2, Jose A Cortes-Briones1,2, Toral Surti1,2, Christina Luddy1,2, Mohini Ranganathan1,2, John D Cahill1,2, Andrew R Sewell1,2, Deepak C D'Souza1,2, Patrick D Skosnik1,2.   

Abstract

BACKGROUND: Binding studies have demonstrated that levels of the cannabinoid receptor type-1 are highest in the basal ganglia and cerebellum, two areas critical for motor control. However, no studies have systematically examined the dose-related effects of intravenous delta-9-tetrahydrocannabinol, the primary cannabinoid receptor type-1 partial agonist in cannabis, on broad domains of psychomotor function in humans. AIMS: Therefore, three domains of psychomotor function were assessed in former cannabis users (cannabis abstinent for a minimum of three months; n=23) in a three test-day, within-subject, double-blind, randomized, cross-over, and counterbalanced study during which they received intravenous delta-9-tetrahydrocannabinol (placebo, 0.015 mg/kg, and 0.03 mg/kg).
METHODS: Gross motor function was assessed via the Cambridge Neuropsychological Test Automated Battery Motor Screening Task, fine motor control via the Lafayette Instrument Grooved Pegboard task, and motor timing via a Paced Finger-Tapping Task. In addition, the Cambridge Neuropsychological Test Automated Battery Rapid Visual Processing Task was utilized to determine whether delta-9-tetrahydrocannabinol-induced motor deficits were confounded by disruptions in sustained attention. RESULTS/OUTCOMES: Delta-9-tetrahydrocannabinol resulted in robust dose-dependent deficits in fine motor control (Grooved Pegboard Task) and motor timing (Paced Finger-Tapping Task), while gross motor performance (Motor Screening Task) and sustained attention (Rapid Visual Processing Task) were unimpaired. Interestingly, despite the observed dose-dependent increases in motor impairment and blood levels of delta-9-tetrahydrocannabinol, subjects reported similar levels of intoxication in the two drug conditions. CONCLUSIONS/
INTERPRETATION: These data suggest that while several domains of motor function are disrupted by delta-9-tetrahydrocannabinol, subjective feelings of intoxication are dissociable from cannabinoid-induced psychomotor effects. Results are discussed in terms of the potential neural mechanisms of delta-9-tetrahydrocannabinol in motor structures.

Entities:  

Keywords:  Cannabis; psychomotor; tetrahydrocannabinol

Year:  2018        PMID: 30255720     DOI: 10.1177/0269881118799953

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  12 in total

1.  Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.

Authors:  Suhas Ganesh; Jose Cortes-Briones; Mohini Ranganathan; Rajiv Radhakrishnan; Patrick D Skosnik; Deepak Cyril D'Souza
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

2.  Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).

Authors:  Anahita Bassir Nia; Maria J Orejarena; Leigh Flynn; Christina Luddy; Deepak Cyril D'Souza; Patrick D Skosnik; Brian Pittman; Mohini Ranganathan
Journal:  Psychopharmacology (Berl)       Date:  2022-04-19       Impact factor: 4.530

3.  Acute Cannabigerol Administration Lowers Blood Pressure in Mice.

Authors:  Victoria L Vernail; Sarah S Bingaman; Yuval Silberman; Wesley M Raup-Konsavage; Kent E Vrana; Amy C Arnold
Journal:  Front Physiol       Date:  2022-05-09       Impact factor: 4.755

4.  Simultaneous Alcohol/Cannabis Use and Driving Under the Influence in the U.S.

Authors:  Priscila D Gonçalves; Sarah Gutkind; Luis E Segura; João M Castaldelli-Maia; Silvia S Martins; Pia M Mauro
Journal:  Am J Prev Med       Date:  2022-02-08       Impact factor: 6.604

Review 5.  Cannabis and driving ability.

Authors:  Eric L Sevigny
Journal:  Curr Opin Psychol       Date:  2021-03-17

6.  The Behavioral Sequelae of Cannabis Use in Healthy People: A Systematic Review.

Authors:  Maryam Sorkhou; Rachel H Bedder; Tony P George
Journal:  Front Psychiatry       Date:  2021-02-16       Impact factor: 4.157

7.  Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans.

Authors:  Ying Hu; Mohini Ranganathan; Chang Shu; Xiaoyu Liang; Suhas Ganesh; Awo Osafo-Addo; Chunhua Yan; Xinyu Zhang; Bradley E Aouizerat; John H Krystal; Deepak C D'Souza; Ke Xu
Journal:  Sci Rep       Date:  2020-02-26       Impact factor: 4.379

8.  The Effect of Long-Term Aronia melanocarpa Extract Supplementation on Cognitive Performance, Mood, and Vascular Function: A Randomized Controlled Trial in Healthy, Middle-Aged Individuals.

Authors:  Sanne Ahles; Yala R Stevens; Peter J Joris; David Vauzour; Jos Adam; Eric de Groot; Jogchum Plat
Journal:  Nutrients       Date:  2020-08-17       Impact factor: 5.717

9.  Acute Effects of Cannabis Concentrate on Motor Control and Speed: Smartphone-Based Mobile Assessment.

Authors:  Leah N Hitchcock; Brian L Tracy; Angela D Bryan; Kent E Hutchison; L Cinnamon Bidwell
Journal:  Front Psychiatry       Date:  2021-01-22       Impact factor: 4.157

10.  Galenic Preparations of Therapeutic Cannabis sativa Differ in Cannabinoids Concentration: A Quantitative Analysis of Variability and Possible Clinical Implications.

Authors:  Alessandra Bettiol; Niccolò Lombardi; Giada Crescioli; Valentina Maggini; Eugenia Gallo; Alessandro Mugelli; Fabio Firenzuoli; Roberto Baronti; Alfredo Vannacci
Journal:  Front Pharmacol       Date:  2019-01-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.